Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

BACKGROUND: Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD patients treated with Rituximab. METHODS: In this study, we designed a web-based qu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: Esmaeili, Sara, Abbasi, Mohammad Hossein, Abolmaali, Meysam, Mojtahed, Mohammad, Alavi, Seyedeh Niloufar Rafiei, Soleimani, Sevim, Mokhtari, Mahisa, Hatam, Jaber, Khotbehsara, Samaneh Tanhapour, Motamed, Mohammad Reza, Joghataei, Mohammad Taghi, Mirzaasgari, Zahra, Moghaddasi, Mehdi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8087518/
https://ncbi.nlm.nih.gov/pubmed/33933026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02218-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars